0
Pharmacotherapeutics: Pharmacotherapuetics |

Efficacy of Tiotropium in Patients Aged 6-17 Years With Severe Symptomatic Asthma

Stan Szefler, MD; Jonathan Bernstein, MD; Kevin Murphy; Georges el Azzi; Michael Engel; Petra Moroni-Zentgraf; Ralf Sigmund; Eckard Hamelmann
Author and Funding Information

Department of Pediatrics, Children's Hospital Colorado and the University of Colorado School of Medicine, Aurora, CO


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;150(4_S):969A. doi:10.1016/j.chest.2016.08.1073
Text Size: A A A
Published online

Extract

SESSION TITLE: Pharmacotherapuetics

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM

PURPOSE: We studied tiotropium Respimat® (tioR) add-on to ICS plus other controller medications in 6-17 year-olds with severe symptomatic asthma.

METHODS: Pooled analysis was performed of two 12-week studies comparing tioR 2.5 µg (2 puffs, 1.25 µg) and 5 µg (2 puffs, 2.5 µg) with placebo Respimat® (VivaTinA-asthma, NCT01634152, 6-11 year-olds, and PensieTinA-asthma, NCT01277523, 12-17 year-olds). The primary endpoint was peak FEV1(0-3h) change from baseline at 12 weeks; secondary endpoints included trough FEV1, ACQ, rescue medication use and exacerbations.

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Anticholinergic drugs in asthma therapy. Curr Opin Pulm Med 2017;23(1):103-108.
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543